{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T14:10:09Z","timestamp":1754057409610,"version":"3.41.2"},"reference-count":13,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Entrectinib, a recently approved multikinase inhibitor indicated for advanced ROS1-positive non-small cell lung cancer (NSCLC), has demonstrated significant survival benefits in metastatic disease. However, it carries risks of severe cardiotoxicity. We report the successful management of entrectinib-induced fulminant myocarditis using integrated venoarterial extracorporeal membrane oxygenation (V-A ECMO) and intra-aortic balloon pump (IABP) circulatory support.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case summary<\/jats:title><jats:p>A 71-year-old male diagnosed with lung adenocarcinoma three years ago (ROS1-positive on genetic testing) initiated crizotinib therapy. One week prior to admission, surveillance chest computed tomography(CT) revealed disease progression with increased tumor burden, prompting transition to entrectinib. Seven days post-treatment initiation, he presented to our emergency department with acute-onset palpitations, dyspnea, dizziness, and nausea. Emergent coronary angiography excluded significant stenosis. The patient subsequently developed frequent ventricular premature complexes(VPCs), cardiogenic shock (serum lactate 2.6\u2005mmol\/L), and acute heart failure. Absent cardiac history and negative viral serology supported a diagnosis of drug-induced fulminant myocarditis. V-A ECMO with IABP support was emergently instituted. Remarkable recovery ensued: cardiac function normalized by day 3 (ECMO decannulation), followed by extubation and IABP removal on day 5.After 12 days of hospitalization, the patient was discharged. Ejection fraction (EF) recovered from 10% at admission to 61% at discharge. Follow-up demonstrates sustained cardiac function comparable to discharge status.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Entrectinib demonstrates potential cardiotoxicity in lung adenocarcinoma therapy, necessitating prospective studies to quantify this risk. During treatment, multidisciplinary team (MDT) collaboration is essential for rigorous cardiac function surveillance. This case establishes V-A ECMO with IABP as an effective salvage therapy for drug-induced fulminant myocarditis.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcvm.2025.1626318","type":"journal-article","created":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T05:33:19Z","timestamp":1754026399000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["ECMO combined with IABP for the treatment of fulminant myocarditis caused by the targeted drug entrectinib for lung adenocarcinoma: a case report"],"prefix":"10.3389","volume":"12","author":[{"given":"Qi","family":"Yujuan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ma","family":"Xiaozhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wu","family":"Zhenhua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bai","family":"Yunpeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1158\/2159-8290.CD-16-1237","article-title":"Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1)","volume":"7","author":"Drilon","year":"2017","journal-title":"Cancer Discov"},{"key":"B2","doi-asserted-by":"publisher","first-page":"100332","DOI":"10.1016\/j.jtocrr.2022.100332","article-title":"Long-Term efficacy and safety of entrectinib in ROS1 fusion-positive NSCLC","volume":"3","author":"Drilon","year":"2022","journal-title":"JTO Clin Res Rep"},{"key":"B3","doi-asserted-by":"publisher","first-page":"108018","DOI":"10.1016\/j.lungcan.2024.108018","article-title":"Entrectinib versus crizotinib in Asian patients with ROS1-positive non-small cell lung cancer: a matching-adjusted indirect comparison","volume":"198","author":"Yu","year":"2024","journal-title":"Lung Cancer"},{"key":"B4","doi-asserted-by":"publisher","first-page":"112974","DOI":"10.1016\/j.biopha.2022.112974","article-title":"Entrectinib, a new multi-target inhibitor for cancer therapy","volume":"150","author":"Jiang","year":"2022","journal-title":"Biomed Pharmacother"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e32174","DOI":"10.7759\/cureus.32174","article-title":"Entrectinib-induced heart failure in a patient with metastatic lung adenocarcinoma: a case report","volume":"14","author":"Otsu","year":"2022","journal-title":"Cureus"},{"key":"B6","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s13691-023-00620-y","article-title":"Lethal ventricular arrhythmia due to entrectinib-induced brugada syndrome: a case report and literature review","volume":"12","author":"Futamura","year":"2023","journal-title":"Int Cancer Conf J"},{"key":"B7","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1093\/oncolo\/oyae205","article-title":"Advances and future directions in ROS1 fusion-positive lung cancer","volume":"29","author":"Boulanger","year":"2024","journal-title":"Oncologist"},{"key":"B8","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s40265-021-01503-3","article-title":"Entrectinib: a review in NTRK+ solid tumours and ROS1+ NSCLC","volume":"81","author":"Frampton","year":"2021","journal-title":"Drugs"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1016\/j.jtho.2021.07.030","article-title":"Pharmacovigilance analysis of cardiac toxicities associated with targeted therapies for metastatic NSCLC","volume":"16","author":"Waliany","year":"2021","journal-title":"J Thorac Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"ytae650","DOI":"10.1093\/ehjcr\/ytae650","article-title":"Case report of entrectinib associated fulminant myocarditis","volume":"9","author":"Rundhawa","year":"2024","journal-title":"Eur Heart J Case Rep"},{"key":"B11","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC guidelines on cardio-oncology developed in collaboration with the European hematology association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the international cardio-oncology society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e243946","DOI":"10.1136\/bcr-2021-243946","article-title":"Entrectinib-related myocarditis in a young female patient with metastatic non-small cell lung cancer","volume":"14","author":"Fonseca","year":"2021","journal-title":"BMJ Case Rep"},{"key":"B13","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1161\/CIRCULATIONAHA.117.026386","article-title":"Survival and left ventricular function changes in fulminant versus nonfulminant acute myocarditis","volume":"136","author":"Ammirati","year":"2017","journal-title":"Circulation"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2025.1626318\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T13:49:15Z","timestamp":1754056155000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2025.1626318\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,1]]},"references-count":13,"alternative-id":["10.3389\/fcvm.2025.1626318"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2025.1626318","relation":{},"ISSN":["2297-055X"],"issn-type":[{"type":"electronic","value":"2297-055X"}],"subject":[],"published":{"date-parts":[[2025,8,1]]},"article-number":"1626318"}}